Continuation Study of the Oral AKT Inhibitor GSK2110183

NCT01531894 | Completed Phase 2 Results DMC

• 2 other identifiers: 1151312014-002041-22
• Study Type: interventional
• Target: 11
• Locations: 5 countries
• Sites: 8

Brief Summary

This multicenter, non-randomized, open-label, treatment continuation or 'rollover' study was designed to provide continued access to eligible subjects who had previously participated in a GSK2110183 study (parent study) sponsored by GlaxoSmithKline (GSK) or another research organization working on behalf of GSK. Eligible subjects had previously received clinical benefit from continued treatment and had to have ad an acceptable safety profile with GSK2110183. Subjects who had participated in a GSK2110183 combination study with an approved anti-cancer agent were also be eligible to enroll in this rollover study. Subjects who participated in combination studies with two investigational compounds (one being GSK2110183) were not eligible for this rollover study. Subjects were enrolled by cohort based on the duration and treatment received while in their parent study. Safety assessments (physical examinations, vital sign measurements, 12-lead electrocardiograms, echocardiograms or multiple-gated acquisition scans, clinical laboratory assessments and monitoring of adverse events) were evaluated during this study. Disease assessment were performed using local standard of care imaging practices and criteria appropriate for disease type and location.

Conditions

Cancer

Keywords

solid tumor; GSK2110183; hematologic malignancy; AKT inhibitor; cancer; safety

Outcome Measures

Primary Outcomes (1)

• Number of Participants With at Least One Adverse Events (AEs)

  Adverse Events (AEs) includes Summary of adverse events, drug related AEs, Serious adverse events, adverse events leading to study treatment discontinuation and death.

  from the time of consent until the final study visit up to approx. 76 months

Study Arms (1)

GSK2110183 (afuresertib)

EXPERIMENTAL

All patients received the GSK2110183 (afuresertib) treatment

Drug: GSK2110183 (afuresertib)

Interventions

GSK2110183 (afuresertib) DRUG

Afuresertib is an oral, low nanomolar pan-AKT kinase inhibitor immediate release (IR) 50 mg or 75 mg tablets was to be taken orally with at least 200 mL of water, with or without food, in the morning.

Also known as: ASB183

GSK2110183 (afuresertib)

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Has provided signed informed consent for this study.
• Is currently participating in a GSK2110183 study (monotherapy or in combination with an approved anti-cancer agent) sponsored by GSK or by another research organization working on behalf of GSK.
• Currently benefitting from continued treatment and have an acceptable safety profile with GSK2110183 as determined by the investigator following previous treatment with GSK2110183 either as monotherapy or as part of a combination treatment regimen.
• Continued ability to swallow and retain orally administered study treatment(s) and does not have any clinically significant GI abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowels.
• Male subjects with a female partner of childbearing potential must be willing to continue practicing the same acceptable method of contraception as used in the parent study during the rollover study and for at least 16 weeks after the last dose of GSK2110183.
• Female subjects of childbearing potential, as defined in the parent study, must be willing to continue practicing the same acceptable method of contraception as used in the parent study during the rollover study and for at least 4 weeks after the last dose of GSK2110183.
• Female subjects of childbearing potential, as defined in parent study, must have negative serum pregnancy tests at the time of transition to this study.
• Maintain a performance status score of 0 to 2 according to the Eastern Cooperative Oncology Group (ECOG) scale
• Subjects with Type II diabetes are only allowed if their HbA1C is less than 8 percent at study entry.
• Have adequate organ system function

You may not qualify if:

• Permanent discontinuation of GSK2110183 in the parent study due to toxicity or disease progression.
• Concomitant use of any type of anti-cancer treatment other than studied in the parent protocol.
• Local access to commercially available GSK2110183.
• Current use of a prohibitive medication(s)
• Current use of anticoagulants
• Any unresolved toxicity greater than Grade 2 , except for alopecia, (National Cancer Institute-Common Toxicity Criteria for Adverse Events \[NCI-CTCAE\], version 4.0) from parent study treatment at the time of transition to this study.
• History of HIV infection.
• Peripheral neuropathy greater than Grade 1
• History of hepatitis B or C infection (subjects with evidence of cleared hepatitis B are permitted).
• Evidence of severe or uncontrolled systemic diseases (e.g., unstable, or uncompensated respiratory, hepatic, renal, metabolic or cardiac disease).
• QTcF interval greater than 500 msecs at the time of transition to this study.
• Other clinically significant ECG abnormalities including 2nd degree (Type II) or 3rd degree atrioventricular (AV) block.
• Evidence of current Class II, III, or IV heart failure as defined by the New York Heart Association \[NYHA, 1994\] functional classification system at the time of transition to this study.
• Symptomatic or untreated leptomeningeal, CNS or brain metastases or spinal cord compression at the time of transition to this study.
• Lactating female or female who becomes pregnant prior to transition to this study.

Sponsors & Collaborators

• Novartis Pharmaceuticals: lead

Study Sites (8)

Novartis Investigative Site

Baltimore, Maryland, 21231, United States

Location

Novartis Investigative Site

Boston, Massachusetts, 02115, United States

Location

Novartis Investigative Site

New York, New York, 10029, United States

Location

Novartis Investigative Site

New York, New York, 10065, United States

Location

Novartis Investigative Site

Melbourne, Victoria, 3004, Australia

Location

Novartis Investigative Site

Toronto, Ontario, M5G 1Z6, Canada

Location

Novartis Investigative Site

Galway, Ireland

Location

Novartis Investigative Site

Seoul, 110-744, South Korea

Location

MeSH Terms

Conditions

Neoplasms; Hematologic Neoplasms

Interventions

GSK2110183; afuresertib

Condition Hierarchy (Ancestors)

Neoplasms by Site; Hematologic Diseases; Hemic and Lymphatic Diseases

Results Point of Contact

• Title: Study Director
• Organization: Novartis Pharmaceuticals

novartis.email@novartis.com

862-778-8300

Study Officials

• Novartis Pharmaceuticals

  Novartis Pharmaceuticals

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 9, 2012
• First Posted: February 13, 2012
• Study Start: February 8, 2012
• Primary Completion: June 20, 2018
• Study Completion: June 20, 2018
• Last Updated: July 9, 2019
• Results First Posted: July 9, 2019

Record last verified: 2019-06

Data Sharing

• IPD Sharing: Will share

Locations

KR (1); AU (1); US (4); CA (1); IE (1)